The Dutch Health Care Inspectorate has planned a next GMP inspection of our 2 API production locations in Oss-The Netherlands (Moleneind and Diosite) from November 19th to November 22nd 2013. As our current GMP certificate
On Thursday June 27th, 2013 MSD announced it signed a key agreement that marks a milestone in the negotiation of a transaction to sell the Oss API operations to South-African pharma company Aspen. The deal is expected to be finalized in the late third quarter or early fourth quarter of 2013 following the successful completion of negotiation and execution of additional necessary agreements and regulatory agency due diligence reviews.
The existing third party supply business will not be impacted by this proposed sale. Both MSD and Aspen are committed to ensuring continuity of supply to valued customers in this segment.
For more information please read the attached press release.